Patent · US Active

Uses of IL-15 antagonists for the treatment of autoimmune and inflammatory diseases

US11008374B2 · kind B2 · utility

2Cited by

0References

16Claims

0Family size

Assignees

INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) · FR
UNIVERSITE DE NANTES · FR
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE · FR
UNIVERSITE D'ANGERS · FR

Inventors

Yannick Jacques · Nantes, FR
Erwan Mortier · Nantes, FR
Agnes Quemener · Nantes, FR
Ariane Plet · Nantes, FR

Key dates

Filing date	Dec 12, 2018
Grant date	May 18, 2021
Priority date	—
Expiry date	Feb 10, 2039

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2319/30
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present relates to interleukin 15 (IL-15) antagonists and uses thereof, in particular for the treatment of autoimmune diseases and inflammatory diseases. In particular, the present invention relates to an IL-15 mutant polypeptide having the amino acid sequence as set forth in SEQ ID NO:1 wherein the leucine residue at position 45 is substituted by an aspartic acid residue, the asparagines residue at position 65 is substituted by a lysine residue and the leucine residue at position 69 is substituted by an arginine residue.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.